Lepu Bio-B (02157) fell more than 12% in the intraday period, to a low of HK$4.23. It is already 35% lower than the monthly high of HK$6.5. As of press release, it decreased by 7.52% to HK$4.55, with a turnover of HK$357.44,300.
The Zhitong Finance App learned that Lepu Bio-B (02157) fell more than 12% in the intraday period, to a low of HK$4.23, down 35% from the monthly high of HK$6.5. As of press release, it decreased by 7.52% to HK$4.55, with a turnover of HK$357.44,300.
According to the news, Lepu Biotech previously announced that it plans to place up to 51.17 million new H shares, accounting for 2.99% of the expanded share capital and 3.09% of the expanded H shares. The placement price of each H share is HK$4.58, a 13.09% discount from the closing price of H shares of HK$5.27 on May 16. The total estimated net proceeds are about HK$230 million.
According to the company, it plans to use about 70% of the net proceeds from the placement process for R&D, clinical trials, registration and other work processes of the company's ADC candidate product; about 20% for clinical trials and other work processes of the company's oncolytic virus candidate CG0070; and about 10% to supplement the company's working capital and general corporate use.